Results 41 to 50 of about 46,198 (239)
ATZ‐1 promotes DNA replication efficiency to maintain normal meiotic function
Absence of ATZ‐1 interferes with meiotic DNA replication and cell cycle function via CHK‐1. This causes downstream defects associated with DNA damage and genomic integrity. Taken together, this study suggests that ATZ‐1 influences DNA replication efficiency and cell cycle function to maintain normal meiotic function.
Taylin E. Gourley +5 more
wiley +1 more source
Objectives: Hydroxyurea is been recommended for patients with sickle cell disease (SCD) as it reduces the complications from the disease by increasing the production of fetal hemoglobin.
Yusra Al Nasiri +8 more
doaj +1 more source
BACKGROUND: Sickle cell anemia is a hemoglobinopathy caused by a mutation that results in the production of an abnormal hemoglobin molecule, hemoglobin S (Hb S).
Paulo Florentino Teixeira Neto +4 more
doaj +1 more source
Background: Hydroxyurea therapy is a known effective and safe therapy for the treatmentof sickle cell anemia (SCA). Although it is used worldwide in our Madhya Pradesh basedsetup, it is underutilized due to economic reasons and unaware practitioners ...
Shikha Gupta +3 more
doaj +1 more source
Evolution‐guided yeast complementation reveals functional differences in human PSPH variants
Ancient genomes can help guide which human genetic variants are tested experimentally. This study applies that idea to PSPH, a gene involved in serine biosynthesis, and uses high‐throughput yeast complementation to compare variant function. The findings reveal measurable differences among selected alleles and illustrate the value of evolution‐guided ...
Mauricio Campa‐Álvarez +6 more
wiley +1 more source
Reversal of myelofibrosis by hydroxyurea [PDF]
Abstract: Bone marrow morphology in 39 symptomatic patients with myeloproliferative disorders (polycythaemia vera 15, essential thrombocythaemia 14, idiopathic myelofibrosis 9, myeloproliferative syndrome 1) and elevated platelet counts was studied before and after a median of 18 months of continuous treatment with hydroxyurea.
E, Löfvenberg +3 more
openaire +2 more sources
Evaluation of hydroxyurea genotoxicity in patients with sickle cell disease
Objective To evaluate the induction of DNA damage in peripheral blood mononuclear cells of patients with sickle cell disease, SS and SC genotypes, treated with hydroxyurea.
Emanuel Almeida Moreira de Oliveira +6 more
doaj +1 more source
Ox‐mtDNA fragments escaping from mitochondria drive robust inflammatory responses. A targeted nanoplatform simultaneously inhibits mitochondrial FEN1‐mediated mtDNA cleavage and scavenges ROS, preventing the generation of immunogenic Ox‐mtDNA fragments. The released SeNPs further promote autophagic clearance of cytosolic mtDNA. Consequently, cGAS‐STING,
Wen‐Ling Li +7 more
wiley +1 more source
Melanonychia secondary to hydroxyurea [PDF]
A 69-year-old woman with recently diagnosed, essential thrombocytosis was treated with hydroxyurea (1 g daily) and anagrelide (0.5 mg twice daily) for 4 weeks. Because of well-controlled platelet count, the use of hydroxyurea was suspended. One month later, she presented to our emergency department (ED) with an extraordinarily high platelet count (2 ...
Po-Hua, Su +3 more
openaire +2 more sources
The measurement of urinary hydroxyurea in sickle cell anaemia
Hydroxyurea is increasingly used in the treatment of sickle cell disease (SCD) although there is little evidence on how best to monitor treatment and compliance.
Height, S E +9 more
core +1 more source

